FOLD: Summary for Amicus Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 4:49am EST - Canadian Markets open in 4 hours and 41 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Amicus Therapeutics, Inc. (FOLD)

On Feb 9: 3.49 USD 0.00 (0.00%)

MORE ON FOLD

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Amicus Therapeutics, Inc. (NGM:FOLD) Delayed quote data

Last Trade:	3.49 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	3.49
Open:	N/A
Bid:	3.22 x 100
Ask:	4.32 x 100
1y Target Est:	3.50

Day's Range:	N/A - N/A
52wk Range:	3.21 - 13.50
Volume:	0
Avg Vol (3m):	54,101.6
Market Cap:	79.04M
P/E (ttm):	N/A
EPS (ttm):	-2.37
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Add FOLD to Portfolio

Download Data

HEADLINES

•	Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
	PRNewswire (Fri, Feb 5)

•	Amicus Therapeutics to Announce Fourth Quarter and Year End 2009 Financial Results on February 16, 2010
	PRNewswire (Thu, Feb 4)

•	Bristol & Genzyme Make A Big Move-Call It "Extraordinary Measures"
	at CNBC (Fri, Jan 22)

•	Genzyme: Shire Chomping at the Bit
	at Seeking Alpha (Tue, Jan 19)

•	The Science Of Hollywood
	at CNBC (Thu, Jan 14)

•	AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
	EDGAR Online (Mon, Jan 11)

•	Amicus Therapeutics Outlines 2010 Strategic Priorities and Continued Progress with Product Pipeline
	PRNewswire (Mon, Jan 11)

•	Getting Ready For The Big One In San Francisco
	at CNBC (Fri, Jan 8)

•	Amicus Therapeutics to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
	PRNewswire (Tue, Jan 5)

•	Biotech On The Big Screen
	at CNBC (Thu, Dec 31)

•	Amicus Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
	PRNewswire (Thu, Nov 12)

•	AMICUS THERAPEUTICS INC Financials
	EDGAR Online Financials (Tue, Nov 10)

•	AMICUS THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Wed, Nov 4)

•	AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Tue, Nov 3)

More Headlines for FOLD...

ANALYST

EPS Est (next year) (Dec-09) :	-2.48
EPS Est (in 2 years) (Dec-10) :	-2.07
Avg Rec (current)*:	3.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs, known as pharmacological chaperones, for the treatment of various human genetic dise...

Full Company Profile

Add to Portfolio

Email to a Friend

•